Drug Trial Radar · NCT01308580
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Apr 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,200
Actual
Start
Apr 2011
Primary completion
Aug 2015
Study completion Aug 2015
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Mar 4, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: \- To demonstrate the non inferiority in term of overall survival (OS) of Cabazitaxel 20 mg/m² (Arm A) versus Cabazitaxel 25 mg/m² (Arm B) in combination with prednisone in participants with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen. Secondary Objectives: * To evaluate safety in the 2 treatment arms and to assess if Cabazitaxel 20 mg/m² was better tolerated than Cabazitaxel 25 mg/m². * To compare efficacy of Cabazitaxel at 20 mg/m² and 25 mg/m² for: * Progression Free Survival (PFS) defined as the first occurrence of any of the following events: tumor progression per Response Evaluation Criteria In Solid Tumors (RECIST), prostate-specific antigen (PSA) progression, pain progression or death due to any cause; * PSA Progression; * Pain progression; * Tumor response in participants with measurable disease (RECIST 1.1); * PSA response; * Pain response in participants with stable pain at baseline. * To compare Health-related Quality of Life (HRQoL). * To assess the pharmacokinetics and pharmacogenomics of Cabazitaxel.
Conditions
- Prostate Cancer
Interventions
Cabazitaxel (XRP6258)Drug
Pharmaceutical form: Concentrate and solvent for solution for infusion Route of administration: Intravenous
Prednisone (or Prednisolone)Drug
Pharmaceutical form: Tablet Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From baseline up to death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)
Locations
172 sites in 22 countries. Site status is shown where the registry gives one.
Investigational Site Number 840002
Muscle Shoals, Alabama
Investigational Site Number 840004
Hot Springs, Arkansas
Investigational Site Number 840008
Anaheim, California
Investigational Site Number 840010
La Jolla, California
Investigational Site Number 840001
San Bernardino, California
Investigational Site Number 840021
Stamford, Connecticut
Investigational Site Number 840023
Jacksonville, Florida
Investigational Site Number 840013
Lakeland, Florida
Investigational Site Number 840003
Port Saint Lucie, Florida
Investigational Site Number 840007
New Orleans, Louisiana
Investigational Site Number 840014
Baltimore, Maryland
Investigational Site Number 840005
Rockville, Maryland
Investigational Site Number 840017
Saint Louis Park, Minnesota
Investigational Site Number 840011
Jackson, Mississippi
Investigational Site Number 840016
Lincoln, Nebraska
Investigational Site Number 840015
East Orange, New Jersey
Investigational Site Number 840024
Raleigh, North Carolina
Investigational Site Number 840020
Akron, Ohio
Investigational Site Number 840006
Pawtucket, Rhode Island
Investigational Site Number 840025
Chattanooga, Tennessee
Investigational Site Number 840012
Corpus Christi, Texas
Investigational Site Number 032002
Buenos Aires, Argentina
Investigational Site Number 032001
Rosario, Argentina
Investigational Site Number 032003
Salta, Argentina
Investigational Site Number 032004
Santa Fe, Argentina
Investigational Site Number 036014
Adelaide, Australia
Investigational Site Number 036013
Bankstown, Australia
Investigational Site Number 036010
Box Hill, Australia
Investigational Site Number 036012
Camperdown, Australia
Investigational Site Number 036008
Coffs Harbour, Australia
Investigational Site Number 036001
Concord, Australia
Investigational Site Number 036015
Elizabeth Vale, Australia
Investigational Site Number 036009
Fitzroy, Australia
Investigational Site Number 036007
Garran, Australia
Investigational Site Number 036005
Heidelberg West, Australia
Investigational Site Number 036002
Malvern, Australia
Investigational Site Number 036006
South Brisbane, Australia
Investigational Site Number 036016
Subiaco, Australia
Investigational Site Number 036003
Wahroonga, Australia
Investigational Site Number 036004
Wodonga, Australia
Showing 40 of 172 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.